Ajanta Pharma has reported results for the fourth quarter and year ended March 31, 2016.
The company has posted a rise of 60.97% in its net profit at Rs 135.71 crore for the quarter ended March 31, 2016 as compared to Rs 84.31 crore for the same quarter in the previous year. Total income of the company has increased by 19.26% at Rs 443.26 crore for quarter under review as compared to Rs 371.68 crore for the quarter ended March 31, 2015.
On consolidated basis, the company has posted a rise of 43.39% in its net profit at Rs 106.31 crore for the quarter ended March 31, 2016 as compared to Rs 74.14 crore for the corresponding quarter in the FY15. Total income of the company increased by 13.80% at Rs 429.11 crore for quarter under review as compared to Rs 377.07 crore for the same quarter ended previous year.
For the year ended March 31, 2016, the company has posted a rise of 35.29% in its net profit at Rs 414.48 crore as compared to Rs 306.37 crore for the same period in the previous year. Total income of company increased 17.57% at Rs 1634.11 crore for year under review as compared to Rs 1389.90 crore for the period ended March 31, 2015.
For the year ended March 31, 2016, on the consolidated basis, the company has posted rise of 29.55% in its net profit at Rs 401.41 crore as compared to Rs 309.86 crore for the same period in the previous year. Total income of company has increased by 17.03% at Rs 1744.16 crore for year under review as compared to Rs 1490.35 crore for the period ended March 31, 2015.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: